Virios therapeutics presents phase 2a fibromyalgia trial data on efficacy analyses of key secondary endpoints at the eular european congress of rheumatology

Atlanta--(business wire)--virios therapeutics, inc. (nasdaq: viri), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that clinical data from its phase 2a trial of imc-1 in fibromyalgia (“fm”) is featured in a poster presentation (poster pos0017) at the annual eular european congress of rheumatology, a renowned forum for interaction between medical doctors, sci
VIRI Ratings Summary
VIRI Quant Ranking